AA
AUPH icon

ALPS Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

ALPS Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-61,065
Closed -$675K – 1018
2025
Q3 		$675K Sell
61,065
-11,798
-16% -$129K ﹤0.01% 623
2025
Q2 		$617K Sell
72,863
-25,959
-26% -$208K ﹤0.01% 596
2025
Q1 		$795K Sell
98,822
-16,950
-15% -$137K ﹤0.01% 527
2024
Q4 		$1.04M Buy
115,772
+7,039
+6% +$57.4K 0.01% 471
2024
Q3 		$797K Sell
108,733
-2,827
-3% -$17.5K 0.01% 552
2024
Q2 		$637K Buy
111,560
+9,554
+9% +$50.3K ﹤0.01% 546
2024
Q1 		$511K Buy
102,006
+1,482
+1% +$10.1K ﹤0.01% 588
2023
Q4 		$904K Sell
100,524
-5,287
-5% -$43.5K 0.01% 508
2023
Q3 		$822K Buy
105,811
+673
+0.6% +$6.58K 0.01% 510
2023
Q2 		$1.02M Buy
105,138
+11,206
+12% +$116K 0.01% 487
2023
Q1 		$1.03M Sell
93,932
-2,555
-3% -$22.5K 0.01% 463
2022
Q4 		$417K Buy
96,487
+18,992
+25% +$110K ﹤0.01% 662
2022
Q3 		$583K Sell
77,495
-6,590
-8% -$57K 0.01% 567
2022
Q2 		$845K Buy
+84,085
New +$940K 0.01% 502
2021
Q4 		– Sell
-157,076
Closed -$3.48M – 895
2021
Q3 		$3.48M Sell
157,076
-10,525
-6% -$167K 0.03% 200
2021
Q2 		$2.17M Sell
167,601
-61,176
-27% -$779K 0.02% 310
2021
Q1 		$2.97M Buy
228,777
+962
+0.4% +$14K 0.03% 218
2020
Q4 		$3.15M Buy
227,815
+66,456
+41% +$967K 0.04% 208
2020
Q3 		$2.38M Buy
161,359
+7,815
+5% +$113K 0.04% 210
2020
Q2 		$2.5M Buy
+153,544
New +$2.46M 0.03% 213
2017
Q4 		– Sell
-82,163
Closed -$515K – 845
2017
Q3 		$515K Buy
82,163
+8,056
+11% +$50.8K ﹤0.01% 452
2017
Q2 		$454K Buy
+74,107
New +$499K ﹤0.01% 601

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ALPS Advisors's AUPH Position: Q4 2025 in Review

ALPS Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2025, closing a stake of 61,065 shares — an estimated $675K sold.

ALPS Advisors first reported a position in AUPH in Q2 2017 and held it in 22 quarters. The position peaked at $3.48M in Q3 2021. 255 funds tracked by Wall St. Rank hold AUPH as of Q4 2025.

  • ALPS Advisors reported no remaining Aurinia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • ALPS Advisors sold 61,065 Aurinia Pharmaceuticals shares in Q4 2025, an estimated $675K.
  • ALPS Advisors first reported a position in Aurinia Pharmaceuticals in Q2 2017 and held it in 22 quarters.
  • ALPS Advisors's Aurinia Pharmaceuticals position peaked at $3.48M in Q3 2021.
  • 255 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2025.

Based on ALPS Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.